文献速递细菌感染、耐药与抗菌药物

万古霉素联合氯唑西林治疗金黄色葡萄球菌实验性心内膜炎的疗效

Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

在兔实验性心内膜炎模型中,万古霉素联合氯唑西林对MRSA-277的清除效果显著优于万古霉素单药,与达托霉素相近;对MSSA-678,达托霉素清除赘生物效果最佳。作者提示在MRSA高流行地区,万古霉素联合氯唑西林可作为金黄色葡萄球菌心内膜炎经验治疗的备选方案。

要点

  • 万古霉素联合氯唑西林对MRSA实验性心内膜炎显示协同杀菌活性
  • 达托霉素对MSSA的赘生物清除效果优于氯唑西林
  • MRSA高流行地区可考虑万古霉素联合氯唑西林作为经验治疗备选

核心结论

  • 万古霉素联合氯唑西林对MRSA具有协同杀菌活性
  • 达托霉素对MSSA最有效,对MRSA与万古霉素联合氯唑西林效果相似
  • MRSA高流行地区万古霉素联合氯唑西林可能是金黄色葡萄球菌心内膜炎经验治疗的良好备选

研究设计与样本

  • 兔实验性心内膜炎模型,比较万古霉素联合氯唑西林与万古霉素、氯唑西林、达托霉素单药
  • 体外时间杀菌试验使用标准接种量(10^5 cfu)和高接种量(10^8 cfu),涵盖5株MRSA、1株GISA和5株MSSA
  • 体内模型选用MSSA-678和MRSA-277各一株,采用类人药代动力学模型

主要发现

  • 对MSSA-678,达托霉素清除赘生物13/13(100%),显著优于氯唑西林9/15(60%),P=0.02
  • 对MSSA-678,达托霉素较万古霉素10/14(71%)和万古霉素联合氯唑西林10/14(71%)呈更好活性趋势,P=0.09
  • 对MRSA-277,万古霉素联合氯唑西林清除13/15(87%),显著优于万古霉素8/16(50%),P=0.05
  • 对MRSA-277,万古霉素联合氯唑西林13/18(72%)与达托霉素活性相似,P=0.6
  • 各治疗组赘生物回收菌株复测达托霉素敏感性均与原菌株相同

关键数值与推荐

  • 氯唑西林剂量等效于2 g/4 h静脉给药,达托霉素等效于6 mg/kg/日静脉给药
  • 万古霉素剂量调整至AUC/MIC≥400以优化活性

临床怎么用

  • MRSA高流行地区,金黄色葡萄球菌心内膜炎经验治疗可考虑万古霉素联合氯唑西林
  • MSSA心内膜炎治疗中达托霉素显示较高赘生物清除率
  • 联合方案选择需结合本地MRSA流行情况与药敏结果

局限性

  • 为兔实验性心内膜炎模型,结论外推至人类需谨慎
  • 体内试验仅选用MSSA-678和MRSA-277各一株
  • 未报告临床终点或人体研究数据

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate if the addition of cloxacillin to vancomycin enhances the activity of both monotherapies for treating MSSA and MRSA experimental endocarditis (EE) in rabbits. METHODS: Vancomycin plus cloxacillin was compared with the respective monotherapies and daptomycin. In vitro time-kill studies were performed using standard (105 cfu) and high (108 cfu) inocula of five MRSA, one glycopeptide-intermediate (GISA) and five MSSA strains. One MSSA (MSSA-678) and one MRSA (MRSA-277) strain were selected to be used in the in vivo model. A human-like pharmacokinetics model was applied and the equivalents of cloxacillin 2 g/4 h IV and daptomycin 6 mg/kg/day IV were administered. To optimize vancomycin activity, dosage was adjusted to achieve an AUC/MIC ≥400. RESULTS: Daptomycin sterilized significantly more vegetations than cloxacillin (13/13, 100% versus 9/15, 60%; P = 0.02) and showed a trend of better activity than vancomycin (10/14, 71%; P = 0.09) and vancomycin plus cloxacillin (10/14, 71%; P = 0.09) against MSSA-678. Addition of cloxacillin to vancomycin (13/15, 87%) was significantly more effective than vancomycin (8/16, 50%; P = 0.05) and showed similar activity to daptomycin (13/18, 72%; P = 0.6) against MRSA-277. In all treatment arms, the bacterial isolates recovered from vegetations were re-tested and showed the same daptomycin susceptibility as the original strains. CONCLUSIONS: Vancomycin plus cloxacillin proved synergistic and bactericidal activity against MRSA. Daptomycin was the most efficacious option against MSSA and similar to vancomycin plus cloxacillin against MRSA. In settings with high MRSA prevalence, vancomycin plus cloxacillin might be a good alternative for empirical therapy of S. aureus IE.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Castañeda X, García-De-la-Mària C, Gasch O, et al. Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis. J Antimicrob Chemother. 2021. PMID: 33837406. doi:10.1093/jac/dkab069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。